ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$8.46
-0.21 (-2.42%)
▼
5d:
+2.3%
30d:
-1.74%
90d:
-17.46%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
2d
Smart Money Accumulation
None View Scanner →
Strength: 4.4/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ADMA trading at deep discount. Market pricing in -10.9% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ADMA trading at deep discount. Market pricing in -10.9% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$22.72
Based on 13.8% avg growth
INTRINSIC VALUE TODAY
$14.11
40.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $8.46, which is considered oversold relative to its 30-day fair value range of $8.46 to $9.00. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.6) compared to its historical average (12.2). Remarkably, the market is currently pricing in an annual earnings decline of 10.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $8.16, while resistance sits at $8.88.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+100.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $8.16, while resistance sits at $8.88.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+100.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.46 -
$9.00
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 100.9% below Wall St target ($17.00)
Trading Range Analysis
30-Day Trading Range
$8.46 -
$9.00
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.17
Resistance Level
$8.88
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.59
Wall Street Target
$17.00
(+100.9%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
32.4%
Valuation Discount vs History
-10.9% cheaper
PE vs Historical
8.6 vs 12.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.9%
(market-implied from PE analysis)
1-Year Target
$7.61
(-10%)
2-Year Target
$6.85
(-19%)
3-Year Target
$6.17
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→12)
$8.76
(+4%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 23.6%)
$38.59
(+356%)
Base:
(SPY PE: 8.6, Growth: 23.6%)
$15.99
(+89%)
Bear:
(PE: 7.3, Growth: 23.6%)
$13.59
(+61%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 12.75 | Current EPS (TTM): $0.68
Bull Case
$13.81
(+63%)
Analyst growth 44.9%, PE expands to 14.0
Base Case
$12.56
(+48%)
Market implied 44.9%, PE stable at 12.8
Bear Case
$5.90
(-30%)
Severe decline -20.0%, PE contracts to 10.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.6 to 12.2
Stabilization Target:
$12.02
(+42.0%)
PE Expansion Potential:
+42.0%
Share & Embed Analysis
Last updated: August 02, 2026 3:38 PM ET
Data refreshes hourly during market hours. Next update: 4:38 PM
Data refreshes hourly during market hours. Next update: 4:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$207 | 60 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
